Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02 in Healthy PPD-negative Adults.

Tuberculosis (TB) Clinical Trial

Official title:
Evaluate the Safety, Reactogenicity & Immunogenicity of 2 Antigen Dose Levels of GSK Biologicals' Candidate Tuberculosis Vaccine, Mtb72F/AS02 to Healthy PPD-negative Volunteers Aged 18 to 45 Yrs

Status Completed

Clinical Trial Summary

Vaccination against tuberculosis (TB) /healthy PPD-negative adults aged 18 to 45 years.Three doses of primary vaccination followed by a booster dose after completion of primary vaccination course. Booster vaccination will be given only to subjects receiving the candidate tuberculosis vaccines and not to the subjects receiving active comparators or control.

Clinical Trial Description

The safety and immunogenicity of 2 antigen doses in PPD-negative adults will be evaluated. In addition, 2 active comparator groups of volunteers will receive the vaccine alone without an immunostimulant and 1 control group will receive the adjuvant (AS02) alone to assess the true effect of the candidate tuberculosis vaccine (Mtb72F/AS02). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00291889
Study type	Interventional
Source	GlaxoSmithKline
Contact
Status	Completed
Phase	Phase 1
Start date	July 2004
Completion date	May 2005

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06272812` - A Study to Evaluate the Efficacy, Safety and Immunogenicity of MTBVAC in IGRA Positive Adolescents and Adults Living in a TB Endemic Region.	Phase 2
Active, not recruiting	`NCT01875952` - Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection (HIV/TBL)	Phase 4
Completed	`NCT03929705` - Assessing the Ability of the T-SPOT®.TB Test
Recruiting	`NCT03808636` - Innovative Reagents for Improving Rapid Diagnosis of Mycobacterial Infections
Completed	`NCT01879163` - Phase I Trial Evaluating Safety and Immunogenicity of MVA85A-IMX313 Compared to MVA85A in BCG Vaccinated Adults	Phase 1
Completed	`NCT00146744` - Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02A in Healthy PPD-positive Adults	Phase 2
Recruiting	`NCT04333485` - Tuberculosis (TB) Aftermath	N/A
Completed	`NCT00730795` - Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine Given to PPD-Negative Adults	Phase 1
Completed	`NCT00600782` - Immunogenicity and Safety of a Candidate Tuberculosis (TB) Vaccine Given to Healthy Adults in a TB-endemic Region	Phase 2
Withdrawn	`NCT04243031` - QuantiFERON Access Clinical Performance Study Protocol